Pliant Therapeutics (PLRX) Income towards Parent Company (2019 - 2026)

Pliant Therapeutics (PLRX) has 8 years of Income towards Parent Company data on file, last reported at -$20.0 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$20.0 million, up 64.32% year-over-year; the trailing twelve-month figure through Mar 2026 was -$111.4 million (up 49.26% YoY), and the FY2025 annual result was -$147.5 million, up 29.86% from the prior year.
• Income towards Parent Company climbed to -$20.0 million in Q1 2026 per PLRX's latest filing, from -$21.7 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$20.0 million in Q1 2026 and troughed at -$57.8 million in Q3 2024.
• A 5-year average of -$39.0 million and a median of -$41.1 million in 2023 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2026: Income towards Parent Company plunged 42.92% in 2022, then surged 64.32% in 2026.
• A 5-year view of Income towards Parent Company shows it stood at -$35.1 million in 2022, then fell by 17.25% to -$41.1 million in 2023, then decreased by 20.98% to -$49.7 million in 2024, then jumped by 56.27% to -$21.7 million in 2025, then gained by 7.86% to -$20.0 million in 2026.
• Business Quant data shows PLRX's Income towards Parent Company at -$20.0 million in Q1 2026, -$21.7 million in Q4 2025, and -$26.3 million in Q3 2025.